US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Crinetics Pharmaceuticals, Inc. - Common Stock
(NQ:
CRNX
)
84.95
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crinetics Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
July 07, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
The market is filled with gapping stocks in Tuesday's session.
↗
July 07, 2026
Via
Chartmill
Discover the top movers in Tuesday's pre-market session.
↗
July 07, 2026
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
July 07, 2026
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay...
Via
Benzinga
Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q1 Expectations on Strong PALSONIFY Launch, Stock Slips After Hours
↗
May 07, 2026
Via
Chartmill
Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q4 Revenue Estimates on First Product Sales
↗
February 26, 2026
Via
Chartmill
CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
July 06, 2026
From
Halper Sadeh LLC
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
July 06, 2026
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The...
Via
Benzinga
Monday's after hours session: top gainers and losers
↗
July 06, 2026
Via
Chartmill
Vertex to Acquire Crinetics Pharmaceuticals
July 06, 2026
From
Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
Via
Business Wire
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
June 30, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
June 14, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
June 14, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
June 02, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
June 02, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
May 22, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
↗
May 18, 2026
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.
Via
The Motley Fool
Topics
ETFs
Regulatory Compliance
Crinetics (CRNX) Q1 2026 Earnings Transcript
↗
May 08, 2026
Crinetics (CRNX) Q1 2026 Earnings Transcript
Via
The Motley Fool
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 07, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
April 27, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
↗
March 27, 2026
This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
March 26, 2026
Application supported by comprehensive clinical program, including two positive Phase 3 trials evaluating once-daily oral paltusotine in acromegaly
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
↗
March 13, 2026
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.
Via
The Motley Fool
Topics
Regulatory Compliance
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know
↗
March 13, 2026
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
↗
March 13, 2026
Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.
Via
The Motley Fool
Topics
Regulatory Compliance
Crinetics (CRNX) Q4 2025 Earnings Call Transcript
↗
February 26, 2026
Crinetics (CRNX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
February 05, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
January 28, 2026
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused...
Via
Finterra
Topics
Economy
Intellectual Property
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
January 26, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
